Dr. Brian Druker's most significant contribution was the development of the drug Imatinib, also known by its brand name Gleevec. Imatinib specifically targets the BCR-ABL protein produced by the Philadelphia chromosome abnormality in CML patients. Before the advent of Imatinib, the prognosis for CML was grim, with limited treatment options available. Imatinib revolutionized the treatment of CML by turning it from a fatal disease into a manageable chronic condition.
